Encoded Therapeutics has raised $275 Million in New Series F Funding

According to filings with the U.S. Securities and Exchange Commission, Encoded Therapeutics has raised $275,000,000.00 in new Series F funding. The federal securities law requires the notice to be...

Craig Etkin

October 7, 2026 2 Min Read

11 0

According to filings with the U.S. Securities and Exchange Commission, Encoded Therapeutics has raised $275,000,000.00 in new Series F funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

Investors in the company’s current round of funding include: GV, ARCH Venture Partners, Braidwell LP, Farallon Capital Management, Illumina Ventures, Invus, Janus Henderson Investors, Matrix Capital Management, Nolan Capital, RTW Investments, SoftBank Vision Fund 2, and Venrock

About Encoded Therapeutics
Encoded Therapeutics is a clinical-stage biotechnology company developing one-time, precision genetic medicines for severe neurological and central nervous system (CNS) disorders, with a particular focus on disease-modifying gene therapies that address the underlying biology of these conditions. The company uses a proprietary vector engineering and cell-selective targeting and regulation platform to achieve highly targeted control of gene expression in specific cell types in the brain and peripheral nervous system, aiming for potent, precise and durable modulation of disease-relevant genes. Encoded is building an internally developed, wholly owned pipeline of best- and potentially first-in-class therapies, starting with its lead program ETX101 for SCN1A-positive Dravet syndrome, and additional programs such as ETX201 for Angelman syndrome, as well as candidates for common CNS conditions including chronic pain and Alzheimers disease. The company operates an end to end genetic medicines product engine that spans discovery, preclinical research, process sciences, in house GMP manufacturing, and clinical development, positioning it to take gene therapies from concept to clinic and to make gene therapy a viable option across both rare and common diseases. Headquartered in South San Francisco, California, with additional facilities in Research Triangle Park, North Carolina.

To learn more, visit https://encoded.com/
Linkedin: https://www.linkedin.com/company/encodedtherapeutics/

Contact:
Kartik Ramamoorthi, Chief Executive Officer
https://www.linkedin.com/in/kartik-ramamoorthi-a2338026b